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an economic perspective, vaccination with these coverage
levels is cost-beneﬁcial.
PIN36
INCIDENCE OF SEVERE SEPSIS IN THE
NETHERLANDS:A POINT PREVALENCE SURVEY
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OBJECTIVES: To determine the annual incidence of
severe sepsis in the Netherlands by performing a point-
prevalence survey in multiple intensive care units.
METHODS: ICU’s were invited to participate in a one-
day survey and monitor patients during the ﬁrst 24 hours
of their stay, if they were admitted with a proven/
suspected infection. Patient-speciﬁc questionnaires cap-
tured demographic and clinical information, presence of
Systemic Inﬂammatory Response Syndrome (SIRS), and
the functional status of seven organ systems. The annual
national incidence was calculated from the results of the
survey following two approaches: 1) by multiplying the
survey incidence (patients/day) with the number of days
per year, corrected for the fact that the survey was held
on a weekday, and 2) by using the relation P = I ·D (P for
prevalence, I for incidence and D for duration of stay) in
which P was known from the survey and D was estimated
as the geometrical mean of duration-to-date. RESULTS:
Forty-seven ICU’s participated (in 43 general and 4 
university hospitals), representing 42% of the national
admission capacity. During the study-period, 18 patients
meeting criteria for severe sepsis were newly admitted,
and another 116 patients with severe sepsis were already
present. According to the ﬁrst calculation method, the
annual incidence of severe sepsis was 13,137 ± 2,821
patients, whereas the second method, with an estimated
D of 13.3 ± 1.1 days, lead to a calculated incidence of
8,643 ± 929 patients/year. CONCLUSIONS: Using 
the results from a point-prevalence survey, different
approaches lead to different outcomes. Both approaches
hold advantages and disadvantages. The second method
is considered superior because it is based on a larger 
population and is less sensitive to daily variations.
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OBJECTIVES: HPV DNA has been detected in up to
99.7% of all cervical cancers, and infection with 2 types
(HPV-16, 18) accounts for more than 50% of cases. 
We developed a computer-based Markov model of the
natural history of HPV infection and cervical carcino-
genesis to project the impact of a prophylactic vaccine
against HPV 16/18 infection on the age-speciﬁc incidence
and lifetime risk of invasive cervical cancer, precursor 
cervical lesions, and type-speciﬁc infection with HPV.
METHODS: A comprehensive literature review was con-
ducted to deﬁne plausible ranges for parameter values and
the model was then calibrated to the best available 
population-based data. We explored the impact of alter-
native assumptions about vaccine efﬁcacy, waning immu-
nity, and competing risks associated with non-16/18 HPV
types in vaccinated women. RESULTS: The model pre-
dicted a peak age-speciﬁc cancer incidence of 90 per
100,000 in the 6th decade, a lifetime cancer risk of 3.7%,
and a reproducible representation of type-speciﬁc HPV
within precancerous lesions and cervical cancer. A vaccine
that prevented 98% of persistent HPV 16/18 was asso-
ciated with an approximate equivalent reduction in
16/18-associated cancer and a 51% reduction in total cer-
vical cancer. A vaccine that prevented 75% of persistent
HPV 16/18 was associated with a 70% to 83% reduction
in 16/18-associated cancer cases. Several modeling
assumptions were identiﬁed that resulted in ampliﬁcation
or blunting of the vaccine’s effect on outcomes—however,
when the vaccine was either very ineffective (e.g., less
than 20% efﬁcacy) or very effective (e.g., more than 80%
efﬁcacy), the differences in projected outcomes associated
with these were minimal. CONCLUSIONS: A prophy-
lactic vaccine that prevents persistent HPV 16/18 
infection can be expected to signiﬁcantly reduce HPV-
16/18-associated LSIL, HSIL and cervical cancer.
OTHER DISEASES/DISORDERS—Economic
Outcomes
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AN ECONOMIC EVALUATION OF 
NOVOSEVEN IN THE MANAGEMENT OF
HAEMOPHILIA PATIENTS WITH INHIBITORS 
IN SLOVAKIA
Hart WM
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OBJECTIVES: It was hypothesised that the total cost of
managing a bleed in haemophilia patients with high titre,
high responding inhibitors (from initiation of the bleed to
resolution) by FEIBA or NovoSeven would be compara-
ble due to a higher ﬁrst-line efﬁcacy despite the greater
cost of NovoSeven. METHODS: Direct costs were 
compared from the perspective of the National Health
Service. Resource utilisation was based on a retrospective
analysis of bleeding episodes treated in Slovakia during
the period 1990–2001. Clinical outcomes were based on
a review of the international literature, data obtained
from the retrospective analysis and the consensus of an
expert panel of ﬁve Slovakian. A decision analytic eco-
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nomic model was constructed using DATA 3.3. The
model enables a cohort of individuals to be followed
sequentially from bleed initiation, taking into considera-
tion ﬁrst-line efﬁcacy, bleed continuation, switching to
other products, re-bleeds and bleed cessation. RESULTS:
Most patients were treated on an outpatient or home
therapy basis. First-line efﬁcacy was assumed to be 79%
and 95.9% for FEIBA and NovoSeven respectively. 90%
of patients would be switched from FEIBA to NovoSeven
if FEIBA failed to stop a bleed. Total process costs from
initiation to cessation in the baseline case were 286,966
SKK for FEIBA and 281,143 SKK for NovoSeven. CON-
CLUSIONS: The analysis indicated that the key economic
drivers were the cost of the haemostatic agents, the dose
used and the ﬁrst-line probability of controlling the bleed.
It could be concluded that the use of NovoSeven for ﬁrst-
line, high titre, high responding patients was not only 
justiﬁed on a clinical basis but also from an economic
point of view since there was cost equivalence with
FEIBA. The results of this study should generate debate
amongst haematologists concerning management guide-
lines for the treatment of bleeding episodes in
haemophilia patients with inhibitors.
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OBJECTIVES: In Latin America and Asia, individuals
with hemophilia are often treated with cryoprecipitate 
as it is a component derived from a unit of whole blood,
thus maximizing the economic and potential medical
beneﬁt of blood bank services. However, the risk of
acquiring blood-borne viral infections is higher with cry-
oprecipitate than with factor concentrates. This is because
the risk of acquiring blood-born infections increases with
each exposure and has a cumulative effect over a person’s
life. We use available data to show that any acquisition
cost savings or societal beneﬁts that occur with the use of
cryoprecipitate may be offset by greater total healthcare
costs to treat transmissible viruses. METHODS: A model
of one Asian country was employed to test the system. A
literature review was conducted to obtain estimates of 
the prevalence and incidence of infectious agents in the
donating population and therefore the blood supply and
costs of treating the subsequent diseases. Epidemiological
and health care cost data from international health 
organizations and regional experts in the treatment of
hemophilia was utilized. This data forms the basis of an
economic and outcomes model for hemophilia treatment.
RESULTS: Based on the data identiﬁed in this particular
country, the risk of exposure to HIV in individuals treated
with cryoprecipitate is substantial: 4% after 5 years of
treatment and it doubles after 10 years of treatment. Over
a lifetime—60 years of treatment—it grows to 40%. The
cost of treating AIDS in this region is high and immedi-
ate cost savings achieved by using cryoprecipitate are
offset by future overall treatment costs of blood-borne
infections. CONCLUSIONS: The model is useful for 
estimating total treatment costs and outcomes for hemo-
philia patients at risk for developing blood borne infec-
tions. The model incorporates a sensitivity analysis option
allowing users to modify parameters speciﬁc to their
country.
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OBJECTIVE: In health care an increasing demand for
care and relatively declining funds go together causing
problems such as waiting lists and reduction of beds. The
objective of this study was to shorten the length of 
hospital stay and to improve efﬁciency of care in joint
replacement surgery. To attain this objective, changes
were made in the care process: pre-admission screening
and medical care during and after admission were geared
to one another and rehabilitation programme after
surgery, taking place in a living room. METHODS: The
study design was a prospective cohort study with two
patient cohorts. The intervention cohort was treated
according to the new protocol. The control cohort
received usual care. The joint recovery group consisted of
48HR patients and 30KR patients; the control group
consisted of 50HR patients and 32KR patients. Both
groups were prospectively followed for six months.
Improvements in hip and knee function were calculated
using baseline and six months function scores. Total 
hospital costs were calculated using length of stay and
average costs per hospital day. Health state utilities were
obtained by the EQ-5D, and were used to calculate
QALYs (one year time horizon). Subsequently, a cost-
effectiveness analysis has been performed. RESULTS:
Mean age was 64.4 years. Hip and knee function
improved in both groups (no signiﬁcant differences).
Length of stay decreased, causing substantial cost savings.
Slightly more QALYs were generated in the intervention
group. CONCLUSIONS: No differences between the
groups in function improvement were observed. Joint
recovery led to a 53% reduction in hospital days, as com-
pared to usual care. As a consequence, hospital costs were
almost halved in both intervention groups. Therefore, our
conclusion is that joint recovery is more effective and 
less costly for both joint replacement groups, and thus
dominates usual care.
